* 45 pct progression-free survival benefit over Xeloda
* 55 pct PFS benefit over infused chemotherapies
By Bill Berkrot
NEW YORK, May 14 (Reuters) - Avastin when added to oral or infused chemotherapies significantly increased the time patients with advanced breast cancer live without the disease worsening, according to data from a late-stage clinical study.
Swiss drugmaker Roche Holding AG ROG.VX, which gained full rights to Avastin with its acquisition of Genentech, said in November that the drug had met the main goal of the study.
Detailed results from the 1,237-patient Ribbon-1 study, which was required following conditional U.S. approval of Avastin for use in breast cancer, will be presented June 1 at the American Society of Clinical Oncology meeting in Orlando, Florida.
ASCO released summaries of hundreds of cancer studies on Thursday ahead of its scientific meeting.
In one arm of the trial, patients who received Avastin and the oral chemotherapy Xeloda saw a 45 percent improvement in progression-free survival compared with those who got Xeloda alone.
The median time without the disease advancing — or the point at which half the patients had cancer progression — was 8.6 months in the Avastin group compared with 5.7 months with Xeloda alone, researchers said.
In the other arm, patients who got Avastin combined with standard infused chemotherapy — taxane or anthracycline — had a 55 percent increase in time they lived without the disease worsening compared with chemotherapy alone.
In this case the median time without disease progressing was 9.2 months with Avastin versus 8.0 months without.
Avastin, developed by Genentech and known chemically as bevacizumab, was originally approved to treat colon cancer and has since gained a U.S. Food and Drug Administration nod to treat lung, breast and brain cancers.
The FDA breast cancer approval for patients with advanced disease who are not eligible for Roche’s Herceptin was conditional and required two late-stage confirmatory studies. Ribbon 1 was the second required study needed for full U.S. approval, which Roche is awaiting. (Reporting by Bill Berkrot, editing by Dave Zimmerman)